Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDQJEZ)

Drug Name

PF-06952229 Drug Info

Synonyms

SCHEMBL16879380; BDBM280355; US10030004, Compound 22; NSC826119; NSC-826119; HY-136244; CS-0120989; PF06952229; ClC=1C=CC(=C(C1)C1=NC=C(C(=C1)NC1=CC=NC=C1C(=O)NC(CO)CO)C(C)C)F; 1801333-55-0; Synthesis of 4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]pyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 118211239
TTD Drug ID: DMDQJEZ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TGF-beta receptor type I (TGFBR1)	TTP4520	TGFR1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
TGF-beta receptor type I (TGFBR1)	DTT	TGFBR1	6.123	5.573	5.6	5.399

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
TGF-beta receptor type I (TGFBR1)	DTT	TGFBR1	2.62E-01	0.27	1.01

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03685591) PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.